Journal of Neural Transmission

, Volume 108, Issue 2, pp 215–219

Long-term persistence of symptomatic effect of selegiline in parkinson’s disease, a two-months placebo-controlled withdrawal study

  • A. Negrotti
  • G. Bizzarri
  • S. Calzetti
Article

Summary

Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson’s disease (stage II and III of H⇐p;Y), whose functional impairment had also required a dopaminergic therapy with low-dose bromocriptine. Both motor signs found worsened during the wash-out showed a full recovery to pre-withdrawal condition within two months after reinstitution of the drug.

Keywords

Selegiline Parkinson’s disease withdrawal symptomatic effect 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Calzetti S, Negrotti A, Cassio A (1995) L-Deprenyl as an adjunct to low-dose bromocriptine in early Parkinson’s disease: a short-term, double-blind, and prospective follow-up study. Clin Neuropharmacol 3: 250–257CrossRefGoogle Scholar
  2. Koller WC (1996) Selegiline monotherapy in the treatment of Parkinson’s disease. Neurology 47 [Suppl 3]: 196–199Google Scholar
  3. Myllyla VV, Sotaniemi K, Mäki-Ikola O, Rinne UK, Heinonen EH (1996) Role of selegiline in combination therapy of Parkinson’s disease. Neurology 47 [Suppl 3]: 200–209Google Scholar
  4. Olanow CW, Hauser RA, Ganger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38: 771–777PubMedCrossRefGoogle Scholar
  5. Pålhagen S, Heinonen EH, Hagglund J, Kaugesaar T, Kontants H, Mäki-Ikola O, Palm R, Turunen J, the Swedish Parkinson Study Group (1998) Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51: 520–525PubMedGoogle Scholar
  6. The Parkinson’s Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • A. Negrotti
    • 1
  • G. Bizzarri
    • 1
  • S. Calzetti
    • 1
    • 2
  1. 1.Istituto di NeurologiaUniversità di ParmaParmaItaly
  2. 2.Istituto di NeurologiaParmaItaly

Personalised recommendations